Aucun m\u00e9dicament ne convient \u00e0 tous les patients. On croit que les diff\u00e9rences g\u00e9n\u00e9tiques entre les patients expliquent les diverses r\u00e9actions aux m\u00e9dicaments. La g\u00e9nomique ouvre la voie \u00e0 une m\u00e9decine personnalis\u00e9e, pr\u00e9dictive et pr\u00e9ventive, et la pharmacog\u00e9nomique en particulier utilise les renseignements g\u00e9n\u00e9tiques d\u2019un patient pour pr\u00e9voir les r\u00e9actions individuelles aux m\u00e9dicaments. C\u2019est l\u00e0 un sujet important, car les r\u00e9actions ind\u00e9sirables aux m\u00e9dicaments sont une cause importante d\u2019hospitalisation et de mortalit\u00e9 au Canada, aux \u00c9tats-Unis et en Europe.<\/p>\n
M. Jean-Claude Tardif, autorit\u00e9 en ath\u00e9roscl\u00e9rose \u00e0 l\u2019Institut de cardiologie de Montr\u00e9al de l\u2019Universit\u00e9 de Montr\u00e9al et M. Michael S. Phillips, de l\u2019Institut de cardiologie de Montr\u00e9al \u00e9galement et directeur de la pharmacog\u00e9nomique au Centre d\u2019innovation de G\u00e9nome Qu\u00e9bec et de l\u2019Universit\u00e9 McGill, sont les directeurs du projet Pharmacog\u00e9nomique de l\u2019efficacit\u00e9 des m\u00e9dicaments et toxicit\u00e9 du traitement des maladies cardiovasculaires.<\/p>\n
MM. Tardif et Phillips dirigeront une \u00e9quipe internationale de chercheurs cliniciens et de scientifiques qui s\u2019efforceront de r\u00e9soudre les probl\u00e8mes de r\u00e9actions aux m\u00e9dicaments dans la gestion des maladies cardiovasculaires, ce qui comprend les cardiopathies, l\u2019insuffisance cardiaque globale, l\u2019hypertension et les accidents c\u00e9r\u00e9brovasculaires (ACV). L\u2019\u00e9quipe du projet examinera la toxicit\u00e9 des m\u00e9dicaments hypolipid\u00e9miants, en particulier les statines, qui sont utilis\u00e9es pour traiter l\u2019ath\u00e9roscl\u00e9rose, la concentration de lipides ou de graisses qui r\u00e9tr\u00e9cissent ou bloquent les art\u00e8res. L\u2019\u00e9quipe \u00e9tudiera \u00e9galement l\u2019efficacit\u00e9 de nouveaux agents anti-ath\u00e9roscl\u00e9rotiques. MM. Tardif et Phillips pr\u00e9voient identifier les biomarqueurs pertinents qui pourront ensuite servir \u00e0 \u00e9laborer des tests diagnostiques. Les r\u00e9sultats aideront \u00e0 d\u00e9terminer comment les patients r\u00e9agiront aux traitements de maladies cardiovasculaires, compte tenu de leur profil g\u00e9n\u00e9tique.<\/p>\n
L\u2019\u00e9quipe du projet \u00e9laborera \u00e9galement des lignes directrices en \u00e9thique qui aideront \u00e0 planifier la recherche future en pharmacog\u00e9nomique, ainsi que des mod\u00e8les et des strat\u00e9gies d\u2019int\u00e9gration des connaissances g\u00e9n\u00e9tiques aux pratiques des soins de sant\u00e9.<\/p>\n
(En anglais seulement.)<\/p>\n
Integrated GE3<\/sup>LS Research:<\/strong> Current public policy lags in Pharmacogenomics research Given the sheer number of human participants needed to conduct pharmacogenomics clinical trials, it is important to address the ethical, legal and social issues related to informed consent. This project will support the scientific activities of the GRID project by helping to develop meaningful consent processes that will enhance the informed nature of prospective consent and the protection of participants\u2019 rights. Issues of access to stored tissues, confidentiality and coding will be explored, as will the type of explanations given to research participants. Planned activities include developing academic papers and policy statements on the prospective nature of informed consent, patient confidentiality and governance of DNA banks; hosting a number of working group meetings with key stakeholders to enable exchange of views and perspectives across different disciplines; holding public events and developing a number of public education materials to inform the broader public community about pharmacogenomics research; and archiving all research outputs on the HUMGEN Website<\/p>\n <\/p>\n <\/p>\n","protected":false},"excerpt":{"rendered":" Aucun m\u00e9dicament ne convient \u00e0 tous les patients. On croit que les diff\u00e9rences g\u00e9n\u00e9tiques entre les patients expliquent les diverses r\u00e9actions aux m\u00e9dicaments. La g\u00e9nomique ouvre la voie \u00e0 une m\u00e9decine personnalis\u00e9e, pr\u00e9dictive et pr\u00e9ventive, et la pharmacog\u00e9nomique en particulier utilise les renseignements g\u00e9n\u00e9tiques d\u2019un patient pour pr\u00e9voir les r\u00e9actions individuelles aux m\u00e9dicaments. C\u2019est l\u00e0 […]<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}}},"project-categories":[93],"genome-competitions":[238],"project-sector":[],"genome_centres":[104],"class_list":["post-10544","project","type-project","status-publish","hentry","project-categories-large-scale-science-fr","genome-competitions-concours-iii","genome_centres-genome-quebec-fr"],"acf":[],"yoast_head":"\n
\nGE3<\/sup>LS Project Leaders:<\/strong> Denise Avard and Yann Joly, Universit\u00e9 de Montr\u00e9al
\nSummary<\/u>
\nThe GE\u00b3LS research team will address issues of informed consent and knowledge transfer in the context of pharmacogenomics research. <\/p>\n